Absolute Return Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Absolute Return Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-21,130	Closed	-$477K	–	609
2014 Q2	$477K	Buy	+21,130	New	+$441K	0.01%	850

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Absolute Return Capital's ACAD Position: Q3 2014 in Review

Absolute Return Capital sold out of Acadia Pharmaceuticals (ACAD) in Q3 2014, closing a stake of 21,130 shares — an estimated $477K sold.

Absolute Return Capital first reported a position in ACAD in Q2 2014 and held it in 1 quarter. The position peaked at $477K in Q2 2014. 162 funds tracked by Wall St. Rank hold ACAD as of Q3 2014.

Absolute Return Capital reported no remaining Acadia Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
Absolute Return Capital sold 21,130 Acadia Pharmaceuticals shares in Q3 2014, an estimated $477K.
Absolute Return Capital first reported a position in Acadia Pharmaceuticals in Q2 2014 and held it in 1 quarter.
Absolute Return Capital's Acadia Pharmaceuticals position peaked at $477K in Q2 2014.
162 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2014.

Based on Absolute Return Capital's 13F filing for Q3 2014, filed 14 Nov 2014.